Navigation Links
Novelos Therapeutics Announces Encouraging Results in Ongoing Phase,2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care

NEWTON, Mass.--(BUSINESS WIRE)--Jun 18, 2007 - Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced encouraging results in an ongoing Dana-Farber/Partners Cancer Care (DF/PCC) Phase 2 trial of NOV-002 in combination with carboplatin in platinum-resistant ovarian cancer patients. To date, 10 patients were evaluable for best overall tumor response (assessed at least after 8 weeks / 2 chemotherapy cycles), whereby all 10 women had previously failed three lines of chemotherapy (starting fourth line). 1 patient had a partial response, 5 stable disease and 4 progressive disease. NOV-002 was well-tolerated, further extending the excellent safety profile NOV-002 has demonstrated in previous studies.

The primary objective of this open-label single-arm Phase 2 is to determine the tumor response rate in a cohort of women with platinum-resistant ovarian cancer after treatment with NOV-002 and carboplatin. Up to 25 women may be enrolled in the trial and may receive up to six cycles of NOV-002 and carboplatin. A link to the trial description and contact information is available at www.novelos.com under 'Clinical Trials' section.

"I am encouraged by these preliminary results in platinum-resistant ovarian cancer, with NOV-002 (in combination with carboplatin) apparently slowing disease progression in over half of the treated patients," said Dr. Carolyn Krasner, the Principal Investigator. "Most women, having failed three lines of chemotherapy, would be expected to progress in about eight weeks."

"We look forward to continuing to work closely with Dana-Farber/Partners on developing NOV-002 for this indication," said Harry Palmin, President and CEO of Novelos. "Meanwhile, Novelos remains on-track for full enrollment of our pivotal Phase 3 trial of NOV-002 for lung cancer in the first quarter 2008."

Acco
'"/>




Page: 1 2 3

Related medicine technology :

1. Novelos Therapeutics and MUSC Present Two Posters at AACR 2007 Annual Meeting
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
10. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
11. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
Post Your Comments:
(Date:7/30/2015)... , July 30, 2015 Eisai Inc. announced ... the United States , European Union and ... and MHLW, respectively) for eribulin, for the treatment of ... received prior chemotherapy for advanced or metastatic disease. ... from a pivotal global Phase 3 clinical trial (Study ...
(Date:7/30/2015)... 30, 2015 Future Market Insights ... "Continuous Glucose Monitoring Systems Market: Global Industry Analysis and ... the global continuous glucose monitoring systems market was valued ... to reach US$ 788.4 Mn by 2020, registering a ... 2020. Global continuous glucose monitoring systems market ...
(Date:7/30/2015)... , July 30, 2015  Medimetriks Pharmaceuticals, ... the second Phase III clinical study for Ozenoxacin, ... impetigo.  Medimetriks owns the exclusive U.S. rights to ... trial, conducted at 44 centers with an emphasis ... patients aged 2 months and older with a ...
Breaking Medicine Technology:Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3
... 2011 Zimmer Holdings, Inc. (NYSE: ZMH ; ... the Zimmer NexGen LPS-Flex Mobile Bearing ... the United States.  The LPS-Flex Mobile Bearing knee provides a ... cruciate ligament (ACL), replicating the anatomic center of knee rotation. ...
... Reportlinker.com announces that a new market research ... Merck & Co., Inc.: PharmaVitae Profile ... IntroductionThis analysis examines the historical and forecast performance ... sector. The profile encompasses global company strategy, portfolio ...
Cached Medicine Technology:Zimmer Introduces a Move Forward in Mobile Bearing Knee Design 2Zimmer Introduces a Move Forward in Mobile Bearing Knee Design 3Reportlinker Adds Merck & Co., Inc.: PharmaVitae Profile 2
(Date:8/1/2015)... ... , ... The condition where veins are enlarged and gnarled is known as ... discomfort. Those who spend a lot of time on their feet and standing are ... what it can to create awareness and provide a cure in observance of Senior ...
(Date:8/1/2015)... ... 2015 , ... Brig and Lita Hart, icons of the network marketing industry ... Home mission with the HOPE Movement of EvolvHealth. In what has been a long-term ... agreed to join their missions of purpose together to change the course of the ...
(Date:8/1/2015)... ... ... Lume Wellness creators Alex, Robert, and Sam have announced update 3.0.1 to ... , The app is designed to track various metrics of wellness, including physical activity, ... health and use this information for positive behavior modification. Lume Wellness keeps track of ...
(Date:8/1/2015)... ... ... Phil Valentine – the Executive Director of Connecticut Community for Addiction Recovery (CCAR) – began ... and heading north. Since that day, Phil has hiked over 1400 miles in nine states. ... family. He visited CCAR and left an inspirational message to his staff: “You can ...
(Date:7/31/2015)... New York (PRWEB) , ... July 31, 2015 , ... ... strut their stuff, Super-Sod debuted their new type of sod called Leisure Time(TM) ... trademark application in process. , To commemorate introduction of this new type of sod, ...
Breaking Medicine News(10 mins):Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 3Health News:Looking for HOPE? Healthy Home Has Evolv’d 2Health News:Looking for HOPE? Healthy Home Has Evolv’d 3Health News:Lume Wellness Launches Health and Fitness Tracker iPhone App 2Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2
... events, from tornados, floods, fires and hurricanes, researchers at ... physiological changes associated with aging and the presence of ... or injury, even death, during a disaster. Investigators ... of 86, who were evacuated for five days due ...
... France, 21 October 2011 A pioneering educational resource, ... chronic hepatitis B, was launched today at an annual ... 26 patient advocacy groups from 14 countries and regions ... ("Patients and Professionals Acting Together for Hepatitis B") programme ...
... FRIDAY, Oct. 21 (HealthDay News) -- Elevated levels of hormones ... number of different elevated hormones rises, so does the risk, ... Women,s Hospital and Harvard Medical School in Boston examined levels ... collected from nurses up to nine years before their health ...
... a higher burden of multiple, large-joint osteoarthritis (OA), and may ... OA." African Americans were also more likely to have knee ... than Caucasians according to the findings reported today in ... College of Rheumatology (ACR). OA is the most ...
... -- The number of American women with precancerous cells ... 2000, and the increase has led to the release Thursday ... Cancer of the vulva -- the outside of the genital ... (HPV), which also causes cervical cancer. The precancerous condition -- ...
... , THURSDAY, Oct. 20 (HealthDay News) -- Most Americans consume ... needed to reduce the amount of dietary salt, according to ... of sodium consumption are associated with increased risk of high ... experts warn. In general, people aged 2 years and ...
Cached Medicine News:Health News:Elderly long-term care residents suffer cognitively during disasters 2Health News:'PATH B,' a comprehensive support program in Europe for patients with chronic hepatitis B launched 2Health News:'PATH B,' a comprehensive support program in Europe for patients with chronic hepatitis B launched 3Health News:Breast Cancer Risk May Rise With High Hormone Levels 2Health News:More African-Americans burdened by osteoarthritis in multiple large joints 2Health News:Rise in Vulvar Precancers Leads to New Guidelines 2Health News:U.S. Diet Still Has Too Much Salt, CDC Warns 2
Industry leader in the design and manufacturing of GP Lenses. Abba holds the CLMA seal of excellence award....
The inventory system designed for Wholesale Distributors and centralized distribution centers for Optical chains....
... Express is a powerful, fully automated information ... productivity, reduce errors, increase profitability, and all ... Express program has been designed and developed ... point of purchase software. This fully integrated ...
Easy to use practice management software....
Medicine Products: